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nducible clindamycin-resistance in clinical staphylococ-
al isolates with reduced vancomycin susceptibility in a
niversity Teaching Hospital
. Olayinka1,∗, A. Olayinka2, A. Obajuluwa1, J. Onaolapo1,
. Olurinola1
Ahmadu Bello University, Zaria, Nigeria
Ahmadu Bello University Teaching Hospital, Shika-Zaria,
igeria
Background: The chemotherapy of staphylococcal infec-
ions has been complicated by evolution of multidrug
esistant strains, especially the methicillin-resistant Staphy-
ococcus aureus (MRSA) now treated with various groups
f antimicrobial agents, including, the glycopeptides
vancomycin); and the macrolides, lincosamides and strep-
ogramin B (MLSB) class of antibiotics. The risk of clinical
ailure during therapy is increasingly being reported while
herapeutic failures due to MLSB-inducible resistance (MLSB-
) is becoming more frequent. The study determined
revalence of inducible erm-mediated clindamycin resis-
ance (MLSB-i) in clinical staphylococcal isolates with
educed vancomycin susceptibility in a University Teaching
ospital was determined.
Methods: Suspected staphylococcal isolates from spec-
men submitted to the Medical Microbiology laboratory
ere screened for vancomycin resistance on vancomycin-
gar screening plates; Brain Heart agar supplemented with
!g/ml vancomycin (BHI-V6); Mannitol Salt agar supple-
ented with 4 !g/ml vancomycin (MSA-V4) and conﬁrmed
y E-test. All isolates with vancomycin MIC of 1.5 to 2
ere tested for MLSB-i by the double-disc diffusion, D-test
sing erythromycin (ER, 15!g) and clindamycin (CL, 2 !g)
iscs placed 15mm-18mm apart on Muller-Hinton agar plates
noculated with the test organism.
Results: A total of 43/195 (22.1%) grew on BHI-V6 within
4hrs while 66/195 (33.8%) grew on MSA-V4 in 24—48 hrs of
ncubation. However, only 36 isolates had vancomycin MIC
f between 1.5 to 2.0. Only 41.6% (15/36) of the isolates
ave a positive D-test indicative of MLSB-i.
Conclusion: This is of clinical importance because MLSB-
S. aureus undergo spontaneous mutation to constitutive
lindamycin resistance at high rate and with potential to
evelop resistance during treatment. Routine testing of
taphylococcal isolates for inducible clindamycin resistance
s recommended in the 2006 CLSI guidelines and help to
hose treatment failures especially for patients infected
ith inducible MLSB isolates as in our hospital.
oi:10.1016/j.ijid.2010.02.393
4.014
ifferent antibiotic treatments in patients suffering from
RSA-mediastinitis after cardiac surgery
. Dohmen ∗, J. Schaefer, W. KonertzCharite Hospital, Medical University Berlin, Berlin, Ger-
any
Background: Methicillin-resistant Staphylococcus aureus
MRSA) poststernotomy mediastinitis is a rare but serious
i
d
mternational Congress on Infectious Diseases (ICID) Abstracts
omplication, which has a great impact on patient’s mor-
idity and mortality. This retrospective study evaluated
ifferent antibiotic therapies, after similar aggressive sur-
ical treatment was performed.
Methods: Between January 2005 and August 2008, 37
atients suffered postoperative from MRSA-mediastinitis.
he mean age was 70.6± 6.5 years, median logistic
uroSCORE was 27.0% (range 5.3 to 62.9%). In all patient’s
amples Vancomycin MIC was <1.0g/mL. There were 3
roups initiated, Vancomycin 2 g/d (group 1;n = 15), Dap-
omycin 6mg/kg (group 2; n = 11) and Linezolid 1200mg/d
group 3;n = 11). The pre-operative risk scores for surgical
ite infection weremeasured in all patients. End-points were
orbidity and mortality.
Results: The total mortality was 13.5% (5/37 pts). Results
re shown in table1. There was a signiﬁcant lower rate of
cute renal failure by using Daptomycin compared to Van-
omycin (*p = 0.016). Antibiotic therapy was changed in ﬁve
atients of group 1 due to therapy failuire. In group 2,
ntibiotic therapy was deescalated in one patient and one
atient was switched in oral therapy. In group 3, therapy was
hanged due to thrombocytopenia in two patients and in one
atient due to therapy failure. There was a trend of lower
ortality in group 2 compared to group 1 and 3, however
his was not statistical signiﬁcant.
Group 1
(n = 15)
Group 2
(n = 11)
Group 3
n = 11)
cute renal failure 46.7% 0%* 27.3%
ialysis 20.0% 0% 27.3%
herapy change 33.3% 18.2% 27.3%
ortality 26.7% 0% 9.1%
Conclusion: Daptomycin decrease signiﬁcantly acute
enal failure compared to Vancomycin therapy in patients
uffering from MRSA-mediastinitis. Furthermore there is
positive trend seen by using Daptomycin in MRSA-
ediastinitis, however future studies with larger patient’s
umbers are needed to conﬁrm this.
oi:10.1016/j.ijid.2010.02.394
4.015
rends in Methicillin resistant staphylococcus aureus
MRSA) minimal inhibitory concentration (MIC) to Van-
omycin over a 2 year period in a community based
ospital
. Murillo1,∗, C. Garcia2, F. Ordieres3
Miami, USA
South Miami hospital, Miami, Fl, USA
South Miami hospital, 33143, Fl, USA
Background: Clinical and laboratory standards institute
CLSI) susceptible range for MRSA isolates to Vancomycin is
stablished at MIC of 2mcg/ml or less, however MRSA iso-
ates with higher MIC within the susceptible range are being
eported more frequently. It has been reported that the
linical response to therapy with vancomycin for patients
nfected with MRSA isolates with MIC’s ≥ 1.5 to 2mcg/ml is
ecreased.
The objectives of the present study were to deter-
ine the MIC to Vancomycin of MRSA blood isolates over
